Targeted interventions for difficult-to-treat asthma

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 1, 2007, Pages 11-20

  Chipps, Bradley E ^a   Harder, Julia M ^b  

^a Capital Allergy and Respiratory Disease Center   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Asthma control; Biomarker; Difficult asthma; Persistent asthma

Indexed keywords

ARFORMOTEROL; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BUDESONIDE; CARMOTEROL; CICLESONIDE; CORTICOSTEROID; ETANERCEPT; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GSK 159797; GSK 597901; INDACATEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; OMALIZUMAB; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; SUPLATAST TOSYLATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADRENAL SUPPRESSION; ASTHMA; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; DYSPHONIA; FRACTURE; GLAUCOMA; GLUCOSE INTOLERANCE; GROWTH RETARDATION; HUMAN; HYDROCORTISONE RELEASE; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; PATIENT CARE; PATIENT COMPLIANCE; PHARYNGITIS; REVIEW; SIDE EFFECT; SKIN DISEASE; SYSTEMATIC REVIEW; THRUSH; TREATMENT RESPONSE;

ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS; HUMANS;

EID: 33846230900     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.1.11     Document Type: Review

References (58)

1. ROBINSON DS, CAMPBELL DA, DURHAM SR, PFEFFER J, BARNES PJ, CHUNG KF: Systematic assessment of difficult-to-treat asthma. Eur. Respir. J. (2003) 22:478-483.
2. BATEMAN ED, BOUSHEY HA, BOUSQUET J et al: Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am. j Respir. Crit. Care Med. (2004) 170:836-844.
3. RABE KF, VERMEIRE PA, SORIANO JB, MAIER WC: Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J (2000) 16:802-807.
4. RABE KF, ADACHI M, LAI CKW et al: Worldwide severity and control of asthma in children and adults: The global Asthma Insights and Reality surveys. J Allergy Clin. Immunol. (2004) 114:40-47.
5. DOLAN CM, FRAHER KE, BLEEKER ER et al: Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann. Allergy Asthma Immunol. (2004) 92:32-39.
6. SULLIVAN SD: The burden of uncontrolled asthma on the US health care system. Manag. Care (2005) 14:4-7.
7. BOULET LP, PHILLIPS R, O'BYRNE P et al: Evaluation of asthma control by physicians and patients: comparison with current guidelines. Can. Respir. J. (2002) 9:417-423.
8. HALTERMAN JS, MCCONNOCHIE KM, CONN KM et al: A potential pitfall in provider assessments of the quality of asthma control. Ambul, Pediatr. (2003) 3:102-105.
9. TEETER JG, BLEEKER ER: Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest (1998) 113:272-277.
10. 2-agonists alone. J. Allergy Clin. Immunol. (2003) 112:1088-1094.
11. CHIPPS BE, SPAHN JD, SORKNESS CA et al: Variability in asthma severity in pediatric subjects with asthma previously receiving short-acting β-agonists. J. Pediatr. (2006) 148:517-521.
12. BOULET LP, BOULET V. MILOT JP: How should we quantify asthma control? A proposal. Chest (2002) 122:2217-2223.
13. SZEFLER SJ, PHILLIPS BR, MARTINEZ FD et al: Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin. Immunol. (2005) 115:233-242.
14. MALMSTROM K, RODRIGUEZ-GOMEZ G, GUERRA J et al: Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Ann. Intern. Med. (1999) 130:487-495.
15. SZEFLER SJ, MARTIN RJ, KING TS et al: Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin. Immunol. (2002) 109:410-418.
16. TANTISIRA KG, LAKE S, SILVERMAN ES et al: Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. (2004) 13:1353-1359.
17. ISRAEL E, CHINCHILLI VM, FORD JG et al: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial, Lancet (2004) 364:1505-1512.
18. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J Respir. Ciit. Care Med (2000) 162:75-80.
19. WECHSLER ME, LEHMAN E, LAZARUS SC et al: β-adrenergic receptor polymorphisms and response to salmeterol. Am. J Respir. Crit. Care Med. (2006) 173:519-526.
20. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. USA (2000) 97:10483-10488.
21. LIMA JJ, ZHANG S, GRANT A et al: Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. (2006) 173:379-385.
22. SILVERMAN ES, DRAZEN JM: Generic variations in the 5-lipoxygenase core promoter, description and functional implications. Am. J Respir. Crit. Care Med. (2000) 161:A402.
23. JATAKANON A. LIM S, BARNES PJ: Changes in sputum eosinophils predict loss of asthma control. Am. J Respir. Crit. Care Med. (2000) 161:64-72.
24. DEYKIN A, LAZARUS SC, FAHY JV et al: Spurum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J. Allergy Clin. Immunol. (2005) 115:720-727.
25. GREEN RH, BRIGHTLING CE, MCKENNA S et al: Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial. Lancet (2002) 360:1715-1721.
26. KHARATONOV SA, GONIO F, KELLY C et al: Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur. Respir. J. (2003) 21:433-438.
27. BERRY MA, SHAW DE, GREEN RH et al: The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin. Exp. Allergy (2005) 35:1175-1179.
28. SMITH AD, COWAN JO, BRASSETT KP et al: Use of enhaled nitric oxide measurements to guide treatment in chronic asthma. N. Engl. J. Med. (2005) 352:2163-2173.
29. SONT JK, WILLEMS LN, BEL EH et al: Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am. J. Respir. Crit. Care Med. (1999) 159:1043-1051.
30. MACGLASHAN Jr DW, BOCHNER BS, ADELMAN DC et al: Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. (1997) 158:1438-1445.
31. BECK LA, MARCOTTE GV, MACGLASHAN D, TOGIAS A. SAINI S: Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin. Immunol. (2004) 114:527-530.
32. HUMBERT M, BEASLEY R, AYRES J et al: Benefits of ornalizurnab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy (2005) 60:309-316.
33. BOUSQUET J, CABRERA P, BERKMAN N et al: The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy (2005) 60:302-308.
34. CORRY DB, KHERADMAND F: Control of allergic airway inflammation through immunomodulation. J Allergy Clin. Immunol. (2006) 117:8461-8464.
35. CRETICOS PS, SCHROEDER JT, HAMILTON RG et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. (2006) 355:1445-1455.
36. HOWARTH PH, BABU KS, ARSHAD HS et al: Tumour necrosis factor (TNF-α) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax (2005) 60:1012-1018.
37. BERRY MA, HARGADON B, SHELLEY M et al: Evidence of a role of tumor necrosis factor (α in refractory asthma. N Engl J Med (2006) 354:697-708.
38. THOMAS PS: Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol, Cell Biol. (2001) 79:132-140.
39. THOMAS PS, HEYWOOD G: Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax (2002) 57:774-778.
40. ALLEN DB, BIELORY L, DERENDORF H, DLUHY R, COLICE GL, SZEFLER SJ: Inhaled corticosteroids: past lessons and future issues. J Allergy Clin. Immunol. (2003) 112:SI-S40.
41. ROHATAGI S, APPAJOSYULA S, DERENDORF H et al: Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J. Clin. Pharmacol. (2004) 44:37-47.
42. JACKSON LD, POLYGENIS D, MCIVOR RA, WORTHINGTON I: Comparative efficacy and safety of inhaled corticosteroids in asthma. Can. J. Glin. Pharmacol. (1999) 6:26-37.
43. BEIVISI MG: Preclinical pharmacology of ciclesonide. Eur. Respir. Rev. (2004) 13:66-68.
44. ROHATAGI S, ARYA V, ZECH K et al: Population pharmacokinetics and pharmacodynamics of ciclesonide. J. Clin. Pharmacol. (2003) 43:365-378.
45. NAVE R, BETHKE TD, VAN MARLE SP ZECH K: Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. (2004) 43:479-486.
46. DYER MJ, HALPIN DMG, STEIN K: Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. BMC Fam. Pract. (2006) 7:34.
47. WEINBRENNER A, HUNEKE D, ZSCHIESCHE M et al.: Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J. Clin. Endocrinol. Metab. (2002) 87:2160-2163.
48. DEROM E, VAN DE WELDE V, MARISSENS S et al: Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm. Pharmacol. Ther. (2005) 18:328-336.
49. HANSEL TT BENEZET O, KAFÉ H et al.: A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin. Ther. (2006) 28:906-920.
50. KALINER MA: Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: a comparison of ciclesonide and fluticasone propionate. Clin. Ther. (2006) 28:319-331.
51. 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs (2005) 14:775-785.
52. PAGE CP MORLEY J: Contrasting properties of albuterol stereoisomers. J Allergy Clin. Immunol. (1999) 104:S31-S41.
53. BUNDSCHUH DS, ELTZE M, BARSIG J, WOLLIN L, HATZELMANN A, BEUME R: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol. Exp. Ther. (2001) 297:280-290.
54. HATZELMANN A, SCHUDT C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol. Exp. Ther. (2001) 297:267-279.
55. ZECH K, DAVID M, SEIBERLING M, WEIMAR C, BETHKE T, WURST W: High oral absolute bioavailability of roflumilast, a new, orally active, once daily PDE4 inhibitor. Eur. Respir. J. (2001) 18(Suppl. 33):20S.
56. BOUSQUET J, AUBIER M, SASTRE J et al: Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy (2006) 61:72-78.
57. AKBARI O: The role of iNKT cells in development of bronchial asthma: a translational approach from animal models to human. Allergy (2006) 61:962-968.
58. ZEIGER RS, SZEFLER SJ, PHILLIPS BR et al: Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J. Allergy Clin. Immunol. (2006) 117:45-52.